Journal Oncology Times
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Explores Durvalumab Plus Ceralasertib in Immunotherapy-Resistant Lung Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0524Published: May 2024Expires: 4/30/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Durvalumab plus Ceralasertib , Lung CancerMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Explores Durvalumab Plus Ceralasertib in Immunotherapy-Resistant Lung Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0524Published: May 2024Expires: 4/30/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Durvalumab plus Ceralasertib , Lung CancerMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Osimertinib + Chemotherapy Improves Survival in Advanced NSCLC
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0424Published: April 2024Expires: 3/31/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Osimertinib and ChemotherapyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Osimertinib + Chemotherapy Improves Survival in Advanced NSCLC ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0424Published: April 2024Expires: 3/31/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Osimertinib and ChemotherapyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Behavioral Economics Can Help Cancer Patients Quit Smoking
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0324Published: March 2024Expires: 2/28/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Tobacco UseMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Behavioral Economics Can Help Cancer Patients Quit Smoking ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0324Published: March 2024Expires: 2/28/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Tobacco UseMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Highlights Impact of Housing Assistance Programs on Cancer Screening
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0224Published: February 2024Expires: 1/31/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer Screening -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Highlights Impact of Housing Assistance Programs on Cancer Screening ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0224Published: February 2024Expires: 1/31/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer Screening -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Treatment for Metastatic Colorectal Cancer With Mutated KRAS G12C
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0124Published: January 2024Expires: 12/31/2025Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: OncologySpecialties: Hematology, OncologyTopics: KRAS G12C , Metastatic Colorectal CancerMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Treatment for Metastatic Colorectal Cancer With Mutated KRAS G12C ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0124Published: January 2024Expires: 12/31/2025Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: OncologySpecialties: Hematology, OncologyTopics: KRAS G12C , Metastatic Colorectal CancerMedia: